Journals / European Journal of Rheumatology / 2017 / Cilt: 4 - Sayı: 1

Serum calreticulin as a novel biomarker of juvenile idiopathic arthritis disease activity

Pages
19–23
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There were statistically significant positive correlations between the serum CRT levels and disease duration, tender joint count, swollen joint count, visual analog scale, erythrocyte sedimentation rate, JADAS-27, C-reactive protein, rheumatoid factor titer, and ultrasonographic grading for synovitis and neovascularization.Conclusion: Elevated serum CRT levels in JIA patients and its correlations with JIA disease activity and severity parameters signified that CRT might be used as a novel biomarker for disease activity and severity in JIA

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to investigate the relations between calreticulin (CRT) serum level and both disease activity and severity parameters in juvenile idiopathic arthritis (JIA).Material and Methods: In this study, 60 children with JIA and 50 age-and-sex-matched healthy subjects were enrolled.
📊
Key Findings & Data:The assessment of the disease activity was done using juvenile arthritis disease activity score 27 (JADAS-27).
💡
Conclusion & Impact:There were statistically significant positive correlations between the serum CRT levels and disease duration, tender joint count, swollen joint count, visual analog scale, erythrocyte sedimentation rate, JADAS-27, C-reactive protein, rheumatoid factor titer, and ultrasonographic grading for synovitis and neovascularization.Conclusion: Elevated serum CRT levels in JIA patients and its correlations with JIA disease activity and severity parameters signified that CRT might be used as a novel biomarker for disease activity and severity in JIA
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to investigate the relations between calreticulin (CRT) serum level and both disease activity and severity parameters in juvenile idiopathic arthritis (JIA).Material and Methods: In this study, 60 children with JIA and 50 age-and-sex-matched healthy subjects were enrolled. The assessment of the disease activity was done using juvenile arthritis disease activity score 27 (JADAS-27). The assessment of disease severity was done via gray-scale ultrasonography (US) and power Doppler US (PDUS). Enzyme-linked immunosorbent assay (ELISA) was used to assay the serum level of human CRT.Results: The mean serum CRT levels in JIA patients was 8.6±1.2 ng/mL and showed a highly significant increase (p=0.001) as compared to the mean serum levels in the controls (5.02±0.77 ng/mL). There were statistically significant positive correlations between the serum CRT levels and disease duration, tender joint count, swollen joint count, visual analog scale, erythrocyte sedimentation rate, JADAS-27, C-reactive protein, rheumatoid factor titer, and ultrasonographic grading for synovitis and neovascularization.Conclusion: Elevated serum CRT levels in JIA patients and its correlations with JIA disease activity and severity parameters signified that CRT might be used as a novel biomarker for disease activity and severity in JIA

🔖

Cite This Article

FAWZY, R. M., HASHAAD, N. I., ELAZEM, A. A. A., YOUSSEF, M. I. (2022). Serum calreticulin as a novel biomarker of juvenile idiopathic arthritis disease activity. European Journal of Rheumatology, Cilt: 4 - Sayı: 1, 19–23. https://ajindex.com/articles/511718

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Haines KA. Juvenile idiopathic arthritis: therapies in the 21st century. Bull NYU Hosp Jt Dis 2007; 65: 205-11
  2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-24
  3. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2: 63-94. [CrossRef] 4. Torp-Pedersen ST, Terslev L. Settings and artefacts relevant in colour/power Doppler ultrasound in rheumatology. Ann Rheum Dis 2008; 67: 143-9. [CrossRef] 5. Duo CC, Gong FY, He XY, Li YM, Wang J, Zhang JP, et al. Soluble calreticulin induces tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 production by macrophages through mitogen-activated protein kinase (MAPK) and NFκB signaling pathways. Int J Mol Sci 2014; 15: 2916-28. [CrossRef] 6. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658-66. [CrossRef] 7. Möller B, Bonel H, Rotzetter M, Villiger PM, Ziswiler HR. Measuring finger joint cartilage by ultrasound as a promising alternative to conventional radiograph imaging. Arthritis Rheum 2009; 61: 435-41. [CrossRef] 8. Torp-Pedersen ST, Terslev L. Settings and artefacts relevant in colour/power Doppler ultrasound in rheumatology. Annals of the Rheumatic Diseases 2008; 67: 143-9. [CrossRef] 9. Naredo E, Rodríguez M, Campos C, Rodrí- guez-Heredia JM, Medina JA, Giner E et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2008; 59: 515-22. [CrossRef] 10. Farheen K, Agarwal SK. Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J Manag Care Pharm 2011; 17(Suppl B): 9-13. [CrossRef] 11. Lin Q, Cao YG, Gao J. Serum calreticulin is a negative biomarker in patients with Alzheimer's disease. Int J Mol Sci. 2014; 15: 21740-53. [CrossRef] 12. Duus K, Pagh RT, Holmskov U, Hojrup P, Skov S, Houen G. Interaction of calreticulin with CD40 ligand, TRAIL and Fas ligand. Scand J Immunol 2007; 66: 501-7. [CrossRef] 13. Kuroki Y, Takahashi M, Nishitani C. Pulmonary co